支氣管擴張：市場展望、流行病學、競爭格局和市場預測報告，2025-2035年

市場概覽

• 預計德國支氣管擴張症市場將經歷溫和至穩定的成長，這得益於診斷技術的改進和新治療方法的出現，市場規模將從 2025 年的 1.08 億美元成長到 2035 年的 1.67 億美元。
• 市場擴張受以下因素支撐：
• 擴大吸入式抗生素和慢性病管理療法的使用
• 提高對非化膿性痰（NCFB）的認知與診斷
• 雖然患者數量的成長較為溫和（年複合成長率為 0.7%），但市場規模的成長是由慢性病治療和復發性病情加重的管理所推動的。
• 未來的成長取決於開發針對潛在發炎和感染疾病的標靶治療，從而改善疾病控制並減少病情加重的頻率。

支氣管擴張概述

支氣管擴張是一種慢性進行性呼吸系統疾病，其特徵是支氣管不可逆性擴張，由持續感染或發炎損害氣道結構所致。此疾病大致分為囊腫纖維化（CF）相關性支氣管擴張和非囊腫纖維化支氣管擴張（NCFB），後者佔大多數病例，其病因多種多樣，包括既往感染疾病（如結核病和肺炎）、免疫力缺乏、自體免疫疾病以及黏液纖毛清除功能障礙。其潛在的病理生理機制是由粘液清除功能障礙、慢性細菌定植（最常見的是銅綠假單胞菌和流感嗜血桿菌）以及持續性嗜中性白血球炎症構成的惡性循環所驅動的。這種惡性循環導致進行性性肺損傷、肺功能下降、復發性急性惡化風險增加。

臨床上，患者表現為慢性咳嗽咳痰、頻繁加重、呼吸困難和疲倦，導致生活品質顯著下降。儘管人們對該疾病的認知不斷提高，疾病負擔日益加重，但治療選擇仍然有限，主要包括症狀治療，例如氣道清理技術、抗生素和支持療法。治療前景正在改變，目前的研究重點是吸入性抗生素、祛痰藥和抗發炎療法，旨在打破感染和發炎的惡性循環，並改善長期預後。

主要亮點

• 在德國，預計確診病例數將從 2025 年的 44,900 例增加到 2035 年的 48,100 例，呈穩定成長趨勢（年複合成長率為 0.7%）。
• 這種疾病的特徵是反覆加重和慢性感染，導致肺功能進行性下降，對醫療保健造成沉重負擔。
• 疾病修正治療的選擇有限，凸顯了巨大的未滿足需求，導致人們更加關注吸入式抗生素和抗發炎藥物。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici SpA
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Bronchiectasis Market Outlook

Thelansis's "Bronchiectasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchiectasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchiectasis Overview

Bronchiectasis is a chronic, progressive respiratory disorder characterized by irreversible dilation of the bronchi, resulting from persistent infection and inflammation that damage airway structure. The disease is broadly classified into cystic fibrosis (CF)-related and non-cystic fibrosis bronchiectasis (NCFB), with the latter accounting for the majority of cases and arising from diverse etiologies including prior infections (e.g., tuberculosis, pneumonia), immunodeficiency, autoimmune diseases, and impaired mucociliary clearance. The underlying pathophysiology is driven by a vicious cycle of impaired mucus clearance, chronic bacterial colonization-most commonly Pseudomonas aeruginosa and Haemophilus influenzae-and sustained neutrophilic inflammation. This cycle leads to progressive lung damage, declining pulmonary function, and increased susceptibility to recurrent exacerbations.

Clinically, patients present with chronic productive cough, frequent exacerbations, dyspnea, and fatigue, resulting in significant impairment in quality of life. Despite increasing disease recognition and burden, therapeutic options remain limited and largely symptomatic, including airway clearance techniques, antibiotics, and supportive care. The treatment landscape is evolving, with ongoing research focused on inhaled antibiotics, mucoactive agents, and anti-inflammatory therapies aimed at breaking the cycle of infection and inflammation and improving long-term outcomes.

Key Highlights

• In Germany, diagnosed prevalent cases are projected to increase from 44.9K in 2025 to 48.1K by 2035, reflecting steady growth (0.7% CAGR).
• The disease is characterized by recurrent exacerbations and chronic infection, contributing to progressive lung function decline and high healthcare burden.
• Limited availability of disease-modifying therapies highlights a significant unmet need, with increasing focus on inhaled antibiotics and anti-inflammatory agents.

Market Overview

• The Germany bronchiectasis market is projected to grow from $108M in 2025 to $167M by 2035, reflecting moderate-to-strong growth driven by improved diagnosis and emerging therapies.
• Market expansion is supported by:
• Increasing adoption of inhaled antibiotics and chronic management therapies
• Rising awareness and diagnosis of NCFB
• Despite moderate patient growth (0.7% CAGR), market value is driven by chronic treatment use and management of recurrent exacerbations.
• Future growth will depend on the development of targeted therapies that address underlying inflammation and infection, improving disease control and reducing exacerbation frequency.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici S.p.A.
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)